An intervention that involves training to recognize facial expressions, and also mimicking these expressions, may help people with multiple sclerosis (MS) who have trouble recognizing facial affect, according to data from a small clinical trial. These findings were reported in the study “Emotional processing intervention (EMOPRINT):…
News
Electrically stimulating certain regions of the brain may help to ease tremors in people with multiple sclerosis (MS), but the specific brain regions needed for stimulation may be unique in MS compared to other tremor-causing diseases, a new study suggests. The study, “Connectomic analysis of unilateral dual-lead…
The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund will be used to support research into multiple sclerosis (MS) as part of its 2022–23 budget. Grant opportunities will focus on increasing access to clinical trials and speeding the development of effective…
Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients given foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…
Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…
About CA$1.35 million ($1.07 million) has been invested in a project that seeks to understand the effects of multiple sclerosis (MS) on a group of people with pediatric-onset disease as they move into adulthood. The three-year investment was from Biogen Canada and Roche Canada — each providing about…
Many people with multiple sclerosis (MS) report new bouts of depression and anxiety as a result of the COVID-19 pandemic, but factors that often influence such mental health concerns were not associated with anxiety or depression in the patient group surveyed for a recent U.S. study. “We found that…
Symptoms of Sjögren’s syndrome, including dry eyes and mouth, were observed among 16 people with multiple sclerosis (MS), three of whom met the diagnostic criteria for Sjögren’s in a recent study. Given this low number, however, it’s unclear if there is a true association between the two diseases,…
NVG-291, an experimental therapy designed to promote nervous system repair, has so far been well tolerated in an ongoing Phase 1 study with healthy volunteers. “The Phase 1 study is progressing very well, and we are encouraged by the data we are seeing so far,” Daniel Mikol, MD, PhD, chief…
While sexual problems are relatively common in women with multiple sclerosis (MS), it can still be difficult to openly discuss their experiences with their doctor. A questionnaire especially tailored for women with MS called the Sexual Dysfunction Management and Expectations Assessment in Multiple sclerosis – Female (SEA-MS-F) may…
Nearly three of every four participants in the CONSONANCE clinical trial, which is evaluating Ocrevus (ocrelizumab) in people with primary or secondary progressive multiple sclerosis (MS), showed no evidence of disease progression after a year of treatment. That’s according to new data presented at the American Academy of…
This year’s Scientific Breakthrough Award, funded by the American Brain Foundation, has been awarded to Stephen Hauser, MD, for helping to understand the genetic basis, immune processes, and treatment of multiple sclerosis (MS). The award recognizes the work of an individual or a team whose research has contributed…
Treatment with Kesimpta (ofatumumab) for more than three years revealed no new or unexpected safety findings, and continued to slow disability progression and prevent the development of new brain lesions in people with relapsing multiple sclerosis (MS), according to new clinical trial data. Information from another trial also…
Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of multiple sclerosis (MS), according to 2.5 years of data from a Phase 2 extension study. These findings — supporting evobrutinib’s therapeutic potential in relapsing MS — were shared in an…
Ublituximab, an experimental therapy for relapsing multiple sclerosis (MS) patients, outperformed Aubagio on a number of disability-related outcomes in the ULTIMATE clinical trials, new data show. The findings were presented in a series of posters at the 2022 American Academy of Neurology (AAN) Annual Meeting, being held in…
Six weeks of aerobic exercise led to benefits in cognition, fatigue, and depression among people with relapsing-remitting multiple sclerosis (RRMS), which may be due to increases in blood levels of a hormone called irisin, according to data from a randomized, controlled trial. “Considering the high prevalence of neuropsychiatric symptoms…
COVID-19 does not seem to be linked to increased disability worsening or more relapses in the long term for people with relapsing-remitting multiple sclerosis (RRMS), an Iranian study suggests. The study was relatively small, the researchers noted, indicating that more research is needed in the future to determine the…
Infection with the herpes simplex virus does not increase the risk of multiple sclerosis (MS), according to a new analysis based on genetic data. The study, “Mendelian Randomization Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis,” was published in Frontiers in…
Mapi Pharma announced that it has been granted a U.S. patent covering the use of GA Depot, a potential long-acting formulation of glatiramer acetate, in people with progressive forms of multiple sclerosis (MS). The U.S. Patent and Trademark Office patent, No. 11,167,003, is titled, “…
Multiple sclerosis (MS) patients treated with Betaseron (interferon beta-1b) had over 90% treatment compliance — the percentage of doses administered — over one year, according to a study of data collected by the BETACONNECT autoinjector and the myBETAapp. After one year, the number of patients still using Betaseron…
Rexall Care Network, a nonprofit organization that is part of the Rexall Pharmacy Group, has launched a campaign to bolster the MS Society of Canada‘s initiatives to support caregivers of people living with multiple sclerosis (MS). The Bubble Campaign, which began March 27 and runs through April 30,…
The National Multiple Sclerosis Society (NMSS) has detailed its Pathways to Cures Roadmap and potential ways of addressing gaps and advancing each of the pathways, with a final goal of finding a cure for multiple sclerosis (MS) in all its forms. Details were in the report, “…
The MS Society of Canada is providing thousands in funding to 66 research projects that aim to accelerate scientific understand of multiple sclerosis (MS) and to improve care for people with the disease. The society announced the winners of its 2022–23 Annual Research Competition in four categories…
The U.S. Food and Drug Administration (FDA) has cleared a Phase 1b/2a trial of PIPE-307, Pipeline Therapeutics‘ investigational myelin-restoring treatment, in people with relapsing-remitting multiple sclerosis (RRMS). The trial will enroll about 45 RRMS patients from multiple U.S. sites who will be randomized to receive either three months…
Reviewing an MRI of one’s brain and seeing lesions on it is a frightening prospect for people with multiple sclerosis (MS). “The lesions, the bright spots on a brain scan, that’s probably the last place in your body most of us want to see things. [It’s] such an important…
A team of researchers has discovered that the key to bypassing the blood-brain barrier — a semipermeable border that protects the brain against toxins in the blood but also blocks potential treatments — is the Unc5B receptor in the endothelial cells that line the tiny blood vessels in the brain.
Eight weeks of hormone therapy was tolerable, and its use may ease the hot flashes and greater disease-related disability this life transition can cause in menopausal women with multiple sclerosis (MS), according to results of a small Phase 1b/2a trial of Duavee, an approved therapy. Public concerns over the safety of…
Exposure to Ocrevus (ocrelizumab) just before conception or during the first three months of pregnancy does not seem to increase the risk of adverse outcomes for women with multiple sclerosis (MS) or their babies, according to a small Australian study. All of the patients stopped taking Ocrevus upon…
A researcher in Barcelona, Spain, has been chosen to receive the 2022 John Dystel Prize for his work advancing the understanding, diagnosis, and treatment of multiple sclerosis (MS). The $40,000 prize, given jointly by the National MS Society and the American Academy of Neurology (AAN), will be…
A four-protein complex, or tetramer, of the protein STAT5 is involved in the development of multiple sclerosis (MS)-like autoimmune disease in mice, a new study shows. The findings point to this protein complex and its signaling pathway as a potential treatment in MS and other autoimmune conditions, scientists noted.